

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 28, 2022**

**Larimar Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36510**  
(Commission  
File Number)

**20-3857670**  
(I.R.S. Employer  
Identification No.)

**Three Bala Plaza East, Suite 506**  
**Bala Cynwyd, Pennsylvania**  
(Address of principal executive offices)

**19004**  
(Zip Code)

**Registrant's telephone number, including area code: (844) 511-9056**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	LRMR	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

Included within Exhibit 99.1 to this Current Report on Form 8-K, and incorporated into this Item 2.02 by reference, is a preliminary estimate of Larimar Therapeutics, Inc.'s (the "**Company's**") cash balance as of December 31, 2021. This estimate is preliminary, is based only on currently available information and does not present all necessary information for an understanding of the Company's financial condition as of December 31, 2021 or the Company's results of operations for the three months or year ended December 31, 2021. This estimate has been prepared by and is the responsibility of the Company's management. The Company's independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this estimate and does not express an opinion or any other form of assurance with respect thereto. Actual results may differ due to the completion of the Company's closing procedures with respect to the fiscal year ended December 31, 2021, final adjustments and other developments that may arise between now and the time the Company's financial results for the three months and year ended December 31, 2021 are finalized. As such, this estimate should not be viewed as a substitute for the Company's full audited financial statements prepared in accordance with U.S. generally accepted accounting principles.

In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01 Other Events.**

On February 28, 2022, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Below is a list of exhibits included with this Current Report on Form 8-K.

<u>Exhibit No.</u>	<u>Document</u>
99.1	<a href="#">Larimar Therapeutics, Inc. Corporate Presentation, dated February 28, 2022*</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

\* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Larimar Therapeutics, Inc.

By: /s/ Carole S. Ben-Maimon, M.D.

Name: *Carole S. Ben-Maimon, M.D.*

Title: *President and Chief Executive Officer*

Date: February 28, 2022



# Larimar Therapeutics

Corporate Presentation

February 2022



# Forward Looking Statements

This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company") and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited to statements regarding the expectations and assumptions regarding the future of the Company's business, including its ability to resolve the clinical hold by the FDA related to CTI-1601 and the timing of such resolution, the Company's ability to develop and commercialize CTI-1601 and other planned product candidates, the Company's planned research and development efforts, and other matters regarding the Company's business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the Company's ability to successfully engage with the FDA and satisfactorily respond to the current request, and future requests, if any, from the FDA for further information and data regarding CTI-1601, the timing and outcomes of Larimar's interactions with the FDA, including with respect to the clinical hold on CTI-1601, the success, cost and timing of the Company's product development activities, non-clinical studies and clinical trials, including CTI-1601 clinical milestones; that clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of CTI-1601 may not be predictive of the results or success of clinical trials, and that clinical trial data are subject to differing interpretations and assessments; the ongoing impact of the COVID-19 pandemic on the Company's clinical trials, manufacturing, regulatory and nonclinical study timelines, the ongoing impact of the COVID-19 pandemic and the potential impact of the Russian invasion of Ukraine on the Company's ability to raise additional capital and general economic conditions; the Company's ability and the ability of third-party manufacturers the Company engages to optimize and scale CTI-1601's manufacturing process; the Company's ability to obtain regulatory approval for CTI-1601 and future product candidates; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; the Company's ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by the Company with the Securities and Exchange Commission (SEC), including but not limited to the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at [www.sec.gov](http://www.sec.gov). These forward-looking statements are based on a combination of facts and factors currently known by the Company and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements, except as required by law.

# Investment Highlights



## **Clinical-stage biotechnology company with a novel protein replacement therapy platform**

Focused on addressing unmet needs in Friedreich's ataxia (FA) and other complex rare diseases based on a platform technology backed by a strong intellectual property portfolio



## **Lead candidate: CTI-1601, a recombinant fusion protein designed to deliver frataxin to mitochondria**

Orphan Drug (US & EU), Rare Pediatric Disease (US), Fast Track (US), & PRIME (EU) designations for FA



## **Double-blind, placebo-controlled Phase 1 proof-of-concept trials in FA patients complete**

Data show dose dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues with daily dosing and that CTI-1601 was generally well tolerated when dosed for up to 13 days  
-Currently on clinical hold; responding to FDA data request to allow initiation of additional clinical studies



## **Deerfield funded company; went public through a reverse merger/PIPE in May 2020**

Shareholder base includes high-quality institutional investors; estimated \$70 million in cash at 12/31/21\*;  
Projected runway at least into 2023, with ability to extend, if needed




FXN: Frataxin

\*This estimate is preliminary and actual results may differ due to the completion of our closing procedures with respect to the fiscal year ended December 31, 2021, final adjustments and other developments that may arise between now and the time the financial results for the 2021 fiscal year are finalized. As such, these estimates should not be viewed as a substitute for our full audited financial statements prepared in accordance with U.S. generally accepted accounting principles.

# Platform Technology is Supported by a Strong IP Portfolio

Pending CTI-1601 patent application, if issued, extends IP into 2040





## Additional CTI-1601 IP protection

- CTI-1601 pending applications cover key biomarkers, analytical tools and quantification methods
- CTI-1601 is eligible for **12 years of market exclusivity** upon approval in the US (independent of patents) and at least **10 years of market exclusivity** upon approval in EU (independent of patents)

# CTI-1601 is Designed to Deliver Additional Frataxin (FXN)

CTI-1601 Maintains the Cleavage Site Between the MTS and Mature Human FXN



The maintenance of the cleavage site allows the CPP and MTS to be removed by mitochondrial processing peptidase to produce mature human FXN in the mitochondria

# Friedreich's Ataxia (FA)

## Rare and Progressive Disease

### Caused by genetic defect resulting in low levels of frataxin

- Patients with FA only produce ~20-40% of normal frataxin levels depending on the tissue, sampling technique, and assay considered<sup>1</sup>
- Affects ~5,000 patients in the U.S. & ~20,000 patients in the EU

### >70% of patients present before age 14

- Initial symptoms may include unsteady posture, frequent falling and progressive difficulty in walking
- By the time symptoms occur, heart damage may have already occurred
- Progressive disease: Symptoms worsen and patients are eventually confined to a wheelchair with speech becoming hesitant and jerky (often referred to as "scanning of speech")

### Life expectancy of 30-50 years

- Early death usually caused by heart disease

### No approved therapies available

- Current treatment options are limited to symptom management



1. E.C. Deutsch et al. Molecular Genetics and Metabolism 101 (2010) 238–245



# Strong Relationship with FARA

## Company has strong relationship with Friedreich's Ataxia Research Alliance (FARA)

- National, non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for FA

## FARA provides industry with several key items

- Assistance with patient recruitment and education
- Access to Global Patient Registry with demographic and clinical information on more than 1,000 FA patients
- Sponsored a Patient-Focused Drug Development Meeting in 2017 resulting in a publication titled "The Voice of the Patient"



# Executive Summary of Phase 1 POC Data

## Safety

CTI-1601 appears to be generally well tolerated at doses up to 100 mg administered daily for 13 days

## Pharmacodynamics

Daily dosing of CTI-1601 resulted in dose-dependent increases in FXN levels from baseline compared to placebo controls in all evaluated tissues

## Pharmacokinetics

Pharmacokinetic analyses support evaluating a once-daily dosing regimen for CTI-1601

## Conclusion

Daily subcutaneous (SC) administration of 50mg and 100mg doses of CTI-1601 resulted in FXN levels in buccal cells that are at, or in excess of, those we would expect to see in phenotypically normal heterozygous carriers (who have FXN levels of ~50% of unaffected persons)




# CTI-1601: Phase 1 Clinical Program in Patients with FA

Program consisted of double-blind, placebo controlled single- and multiple-ascending dose trials

## Phase 1 Development Plan

- Two double-blind, placebo-controlled dosing trials in patients with FA
- Patient dosing began December 2019
- Safety Review Committee assessed all blinded data between each cohort to ensure patient safety



### Single Ascending Dose (SAD)

Eligible patients from SAD trial could enroll in MAD trial

**Number of subjects:** 28

**Dose levels:** 25 mg, 50 mg, 75 mg and 100 mg (subcutaneous administration)

**Treatment Duration:** 1 day

**1° Endpoint:** Safety and tolerability

**2° Endpoints:** PK; PD; FXN levels; multiple exploratory

**Status:** Complete with analysis ongoing



### Multiple Ascending Dose (MAD)

**Number of Subjects:** 27

**Dose Range:** 25 mg, 50 mg, 100 mg (subcutaneous administration)

**Treatment Regimen:** Multiple increasing doses administered subcutaneously over 13 days

**1° Endpoint:** Safety and tolerability

**2° Endpoints:** PK; PD; FXN levels (buccal cells, platelets, optional skin biopsies); multiple exploratory

**Status:** Complete with analysis ongoing






# MAD Trial Patient Enrollment

16 out of 28 patients who participated in the SAD trial enrolled in the MAD trial

MAD Trial Patient Enrollment (n=27)		
Parameter	Statistic	Overall
Participated in SAD trial?		
Yes	n (%)	16 (59%)
No	n (%)	11 (41%)
Cohort 1 (25 mg) Active vs. Placebo		
Active	n (%)	6 (75%)
Placebo	n (%)	2 (25%)
Cohort 2 (50 mg) Active vs. Placebo		
Active	n (%)	7 (78%)
Placebo	n (%)	2 (22%)
Cohort 3 (100 mg) Active vs. Placebo		
Active	n (%)	7 (70%)
Placebo	n (%)	3 (30%)

# Multiple Ascending Dose Study Design

## Treatment Schedules for Each Cohort



## FXN Level Sampling Days Presented for Each Cohort

**Cohort 1 Sampling Days**

<b>Buccal Cells</b>	Baseline, Day 4, Day 13
<b>Skin</b>	Baseline, Day 13
<b>Platelets</b>	Baseline, Day 4, Day 13

**Cohort 2 Sampling Days**



<b>Buccal Cells</b>	Baseline, Day 7, Day 13
<b>Skin</b>	Baseline, Day 13
<b>Platelets</b>	Baseline, Day 7, Day 13

**Cohort 3 Sampling Days**

<b>Buccal Cells</b>	Baseline, Day 7, Day 13
<b>Skin</b>	Baseline, Day 13
<b>Platelets</b>	Baseline, Day 7, Day 13

# Dose Dependent Increases in FXN Levels Observed in Buccal Cells



Daily SC injections of 100 mg CTI-1601 resulted in an ~2.5 fold increase in FXN levels from baseline



\*FXN levels measured via detection of peptide derived from mature FXN; Data represent median and 25<sup>th</sup> and 75<sup>th</sup> percentiles; FXN levels from baseline, Day 4, & Day 13 measurements are shown for data derived from the 25 mg cohort; FXN levels from baseline, Day 7 & Day 13 measurements are shown for data derived from the 50 & 100 mg cohorts; Sample collection days varied in each cohort per the trial protocol



# Dose Dependent Increases in FXN Levels Observed in Skin

Daily SC injections of 100 mg CTI-1601 resulted in an ~3 fold increase in FXN levels from baseline



# Dose Dependent Increases in FXN Levels Observed in Platelets with Daily Dosing


Daily SC injections of CTI-1601 resulted in increases in FXN levels from baseline compared to placebo



\*FXN levels measured via detection of peptide derived from mature FXN; Data represent median and 25<sup>th</sup> and 75<sup>th</sup> percentiles; FXN levels from baseline, Day 4, & Day 13 measurements are shown for data derived from the 25 mg cohort; FXN levels from baseline, Day 7 & Day 13 measurements are shown for data derived from the 50 & 100 mg cohorts; Sample collection days varied in each cohort per the trial protocol

# Increases in FXN Correlated with Increasing CTI-1601 Dose

Individual patient data further supports the dose-dependent effects of CTI-1601 in all tissues studied



\*FXN levels measured via detection of peptide derived from mature FXN; #Two patients in the 100 mg cohort declined skin biopsies  
Day 13 observation excluded from one subject in 25 mg group that did not get a Day 13 dose.

# Data Compare Favorably to FXN Levels Expected in Heterozygous Carriers


Achieved median FXN levels that were >60% of the median FXN levels observed in healthy controls

## Benchmarking Clinical Relevance

- FXN levels in buccal cells and blood have been shown to correlate with neurological function in FA patients<sup>1</sup>
- Patients with FA only produce ~20-40% of normal frataxin levels depending on the tissue considered<sup>2</sup>
- Heterozygous carriers who show no signs of disease have FXN levels of ~50% of unaffected healthy persons<sup>2</sup>

## Comparison to Healthy Controls

- FXN levels were measured in buccal cells from 8 healthy controls using the same assay and sampling technique employed in the Phase 1 MAD trial
- With daily administration, patients in Cohorts 2 & 3 of the Phase 1 MAD trial achieved median buccal cell FXN levels that were >60% of the median FXN levels observed in healthy controls
- Data from additional healthy control buccal cells, skin, and platelets will be collected in a separate non-interventional study



\*FXN levels measured via detection of peptide derived from mature FXN; #Data on file; Data represent median and 25<sup>th</sup> and 75<sup>th</sup> percentiles; FXN levels from baseline, Day 4, & Day 13 measurements are shown for data derived from the 25 mg cohort; FXN levels from baseline, Day 7 & Day 13 measurements are shown for data derived from the 50 & 100 mg cohorts; Sample collection days varied in each cohort per the trial protocol. 1. Lazaropoulos et al. Ann Clin Transl Neurol. 2015 Aug; 2(8): 831-842; 2. E.C. Deutsch et al. Molecular Genetics and Metabolism 101 (2010) 238-245.

**Repeated SC injections of CTI-1601 appear to be generally well tolerated at doses up to 100 mg administered daily for 13 days**

#### **Summary of MAD trial safety data:**

Repeated doses (25 mg, 50 mg, and 100 mg) of CTI-1601 or placebo were administered subcutaneously. 27 patients were dosed in the trial. 26 patients completed the trial. 1 patient receiving CTI-1601 in Cohort 2 (50 mg) withdrew after experiencing mild/moderate symptoms (nausea and vomiting).

- ✓ No serious adverse events (SAEs), important medical events, or treatment-related severe adverse events
- ✓ The most common adverse events were mild and moderate injection site reactions (at least one injection site reaction was seen in 43% of placebo patients and in 100% of CTI-1601 patients)
- ✓ The number and severity of adverse events did not increase with increasing exposure to CTI-1601



## PK analyses support evaluating a once-daily dosing regimen for CTI-1601

### Summary of PK Analyses

- ✓ CTI-1601 was quickly absorbed after subcutaneous administration
- ✓ Dose-proportional increases in exposure observed with increasing doses of CTI-1601
- ✓ Mean half life of CTI-1601 in plasma was approximately 11 hours
- ✓ CTI-1601 appears to be at or close to steady state exposure after 13 days of dosing 100 mg once daily

# Phase 1 Topline Data Demonstrated POC for CTI-1601 in FA

FXN levels in buccal cells & blood have been shown to correlate with disease severity in FA patients<sup>1</sup>

## Safety Data



Repeated SC injections of CTI-1601 appear to be generally well tolerated at doses up to 100 mg administered daily for 13 days

The most common AEs were mild and moderate injection site reactions

No SAEs have been reported

## Frataxin Measurements



Daily SC injections of CTI-1601 resulted in dose-dependent increases in FXN levels from baseline compared to placebo controls in all evaluated tissues

With daily dosing (50mg and 100mg), achieved median FXN levels that were >60% of the median FXN levels observed in healthy controls

## Pharmacokinetic Data



CTI-1601 was quickly absorbed after subcutaneous administration

Dose-proportional increases in exposure observed with increasing doses of CTI-1601

Data support evaluating a once-daily dosing regimen for CTI-1601

# Upcoming CTI-1601 Trials and Regulatory Interactions

Additional analyses from the Phase 1 program planned for presentation at a scientific meeting

Future Planned Trials and Regulatory Interactions Include:



Continued interactions with FDA regarding clinical trials and non-clinical studies, including discussions of resolution of clinical hold



Jive open label extension (OLE) trial for eligible patients who participated in SAD or MAD trials



MAD trial in patients 2 to 17 years of age. Participants eligible to screen for Jive OLE trial



Global double-blind placebo-controlled pivotal trial

# Investment Highlights



## **Clinical-stage biotechnology company with a novel protein replacement therapy platform**

Focused on addressing unmet needs in Friedreich's ataxia (FA) and other complex rare diseases based on a platform technology backed by a strong intellectual property portfolio



## **Lead candidate: CTI-1601, a recombinant fusion protein designed to deliver frataxin to mitochondria**

Orphan Drug (US & EU), Rare Pediatric Disease (US), Fast Track (US), & PRIME (EU) designations for FA



## **Double-blind, placebo-controlled Phase 1 proof-of-concept trials in FA patients complete**

Data show dose dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues with daily dosing and that CTI-1601 was generally well tolerated when dosed for up to 13 days

- Currently on clinical hold; responding to FDA data request to allow initiation of additional clinical studies



## **Deerfield funded company; went public through a reverse merger/PIPE in May 2020**

Shareholder base includes high-quality institutional investors; estimated \$70 million in cash at 12/31/21\*;

Projected runway at least into 2023, with ability to extend, if needed



FXN: Frataxin

\*This estimate is preliminary and actual results may differ due to the completion of our closing procedures with respect to the fiscal year ended December 31, 2021, final adjustments and other developments that may arise between now and the time the financial results for the 2021 fiscal year are finalized. As such, these estimates should not be viewed as a substitute for our full audited financial statements prepared in accordance with U.S. generally accepted accounting principles.



# Larimar Therapeutics

Corporate Presentation

THANK YOU

# Leadership Team




**Carole Ben-Maimon, MD**  
Chief Executive Officer



**Michael Celano**  
Chief Financial Officer



**Nancy Ruiz, MD, FACP, FIDSA**  
Chief Medical Officer



**Jennifer Johansson, JD**  
VP, Regulatory Affairs & Counsel



**Mohamed Hamdani**  
VP, Biostatistics & Data Management




**David Bettoun, PhD**  
VP, Discovery & Non-clinical R&D




**Keith E. Lynch, Jr.**  
VP, Manufacturing and Supply Chain



**John Berman, CPA**  
VP, Finance & Operations



**Noreen Scherer**  
VP, Clinical Operations



**Francis Michael Conway**  
VP, Controller



## Scientific Advisory Board



Russell Clayton,  
DO (Chairman)

Former Chief Medical Officer at Alcresta Therapeutics, a medical device company

Former Senior Vice President of Research and Development at Discovery Labs, a pharmaceutical and medical device company



Giovanni Manfredi,  
MD, PhD

Finbar and Marianne Kenny Professor in Clinical and Research Neurology at Weill Cornell Medicine.

Professor of Neuroscience at Weill Cornell Medicine.



Mark Payne,  
MD

Co-founder of Chondrial Therapeutics, which became Larimar Therapeutics, Inc.

Professor of Pediatrics at Indiana University School of Medicine



Marni J. Falk,  
MD

Executive Director of the Mitochondrial Medicine Frontier Program at The Children's Hospital of Philadelphia (CHOP)

Professor in the Division of Human Genetics, Department of Pediatrics at University of Pennsylvania Perelman School of Medicine

# MAD Trial Patient Demographics

Parameter	Statistic	All placebo (n=7)	25 mg CTI-1601 (n=6)	50 mg CTI-1601 (n=7)	100 mg CTI-1601 (n=7)	All CTI-1601 (n=20)	Overall (n=27)
<b>Sex</b>							
Male	n (%)	5 (71.4)	3 ( 50.0)	4 ( 57.1)	3 ( 42.9)	10 ( 50.0)	15 (55.6)
Female	n (%)	2 (28.6)	3 ( 50.0)	3 ( 42.9)	4 ( 57.1)	10 ( 50.0)	12 (44.4)
<b>Age (years)</b>							
	Mean	25.7	39.7	34.7	28.0	33.9	31.7
	SD	6.37	16.59	9.03	8.96	12.13	11.40
	Median	23	37	36	24	34	28
	Min, Max	20,36	21,65	19,47	20,44	19,65	19,65
<b>Race</b>							
White	n (%)	6 ( 85.7)	6 (100.0)	6 ( 85.7)	6 ( 85.7)	18 ( 90.0)	24 (88.9)
Asian	n (%)	0	0	1 ( 14.3)	1 ( 14.3)	2 ( 10.0)	2 ( 7.4)
American Indian	n (%)	1 ( 14.3)	0	0	0	0	1 (3.7)
<b>Ethnicity</b>							
Hispanic/Latino	n (%)	2 (28.6)	0	0	0	0	2 (7.4)
Not Hispanic/Latino	n (%)	5 (71.4)	6 (100.0)	7 (100.0)	7 (100.0)	20 (100.0)	25 (92.6)



# MAD Trial Patient Disease Characteristics

Parameter	Statistic	All placebo (n=7)	25 mg CTI-1601 (n=6)	50 mg CTI-1601 (n=7)	100 mg CTI-1601 (n=7)	All CTI-1601 (n=20)	Overall (n=27)
<b>Age at Symptom Onset</b>							
	Mean	14.1	24.0	19.3	11.9	18.1	17.1
	SD	5.34	14.48	6.21	6.72	10.37	9.39
	Median	15.0	18.0	19.0	10.0	18.0	16.0
	Min, Max	8,23	12,44	8,28	5,22	5,44	5,44
<b>Age at Diagnosis</b>							
	Mean	18.3	31.5	26.4	15.9	24.3	22.7
	SD	7.87	19.88	4.28	8.21	13.24	12.23
	Median	20.0	25.5	28.0	13.0	27.0	21.0
	Min, Max	9,32	14,64	17,30	5,27	5,64	5,64
<b>Assistive Device</b>							
Walker	n (%)	0	2 (33.3)	3 (42.9)	0	5 (25.0)	5 (18.5)
Wheelchair	n (%)	4 (57.1)	3 (50.0)	1 (14.3)	6 (85.7)	10 (50.0)	14 (51.9)
Other	n (%)	1 (14.3)	0	1(14.3)	0	1 (5.0)	2 (7.4)
None	n (%)	2 (28.6)	1 (16.7)	2 (28.6)	1 (14.3)	4 (20.0)	6 (22.2)



# CTI-1601: Positive Mouse Model Data Support Development

## Proof-of-Concept Demonstrated In Mouse Models of FA

### Cardiac Knock Out Mouse Model Studies (MCK-Cre FXN KO Mouse)

- ✓ Extended survival
- ✓ Demonstrated ability to deliver hFXN to mitochondria
- ✓ Increased in a dose dependent manner, succinate dehydrogenase (SDH) activity. SDH is an FXN dependent enzyme, whose activity is indicative of mitochondrial function.
- ✓ Prevented left ventricle dilation and maintained function

### Neurologic Knock Out Mouse Model Study (Pvalb-CRE FXN KO Mouse)

- ✓ Prevented development of ataxic gait
- ✓ Showed that treated mice survive longer than untreated mice
- ✓ Demonstrated CNS penetration, as hFXN was present in brain, dorsal root ganglia & spinal cord

# CTI-1601 Extends Survival in FXN-deficient KO Mice


Initial Proof of Concept for FXN Replacement Therapy in Cardiac Mouse Model of FA

## Median Survival of MCK-Cre FXN-KO Mice

- 166 days (CTI-1601) vs. 98 days (Vehicle)
- CTI-1601 was administered 10 mg/kg SC every other day

## Survival beyond vehicle mean (107.5 days)

- 87.5% (CTI-1601) vs. 33% (Vehicle)
- Demonstrates that CTI-1601 is capable of delivering sufficient amounts of FXN to mitochondria



CTI-1601 rescues a severe disease phenotype in a well-characterized cardiac mouse model of FA

# CTI-1601 Prevents The Development of Ataxic Gait in KO mice

In-Vivo Efficacy Data in  
Neurologic KO Mouse Model



## Pvalb-Cre FXN-KO mouse

Single dose level: 10 mg/kg CTI-1601 or vehicle given intraperitoneally three times per week

- ✓ hFXN replacement with CTI-1601 **prevents the development of ataxic gait**
- ✓ CTI-1601-treated mice **survive longer** than untreated mice
- ✓ Human frataxin **present in brain, dorsal root ganglia and spinal cord** demonstrating central nervous system penetration



# CTI-1601 Delivers hFXN to Mitochondria in KO Mice

- hFXN concentration within mitochondria increases in a dose-dependent manner
- Given subcutaneously, CTI-1601 functionally replaces hFXN in mitochondria of KO mice
- Succinate dehydrogenase (SDH) activity, which is indicative of mitochondrial function, increases in a dose-dependent manner after administration of CTI-1601; activity plateaus at 30 mg/kg and is equivalent to activity in wild type animals
- Demonstrated normalization of gene expression in cardiac tissue



# CTI-1601 Prevents Left Ventricle Dilation in KO Mice



- Left ventricular (LV) volume increases in systole in untreated mice by 8 weeks (after 4 weeks of dosing with vehicle), but remains similar to wildtype when treated with CTI-1601 (10 mg/kg every other day)
- CTI-1601-treated mice have similar LV volume as healthy controls; echocardiogram shows significant differences between vehicle and CTI-1601 treated (10 mg/kg every other day) KO mice



—●— KO: CTI-1601    —■— KO: Vehicle    —▲— Wild-type: Vehicle

# CTI-1601 Preserves Left Ventricle Function in KO Mice

- Left ventricular (LV) function drops significantly in vehicle treated mice by week 8
- CTI-1601-treated (10 mg/kg every other day) mice have similar LV as healthy controls; echocardiogram shows significant differences between vehicle and CTI-1601 treated KO mice



—•— KO: CTI-1601    —•— KO: Vehicle    —•— Wild-type: Vehicle

# Favorable PK/PD Profile in Healthy Cynomolgus Monkeys

## Study Design (14-Days of CTI-1601 dosing)

6 healthy cynomolgus monkeys (3M / 3F)

## Pre-dosed for 2 days with Vehicle

Pre-dose collection of platelets, cerebrospinal fluid, buccal swab, skin punch  
Dosing starts 15 mg/kg SC BID

## Day 10 (7 days dosing)

Collection of platelets, buccal swab, skin punch

## Day 16 (following 14<sup>th</sup> day of dosing)


Collection of cerebrospinal fluid, platelets, buccal swab, skin punch

- CTI-1601 is bioavailable when given subcutaneously
- Sustained levels of hFXN are found in blood cells (platelets) and peripheral tissues (buccal cells, skin) as early as the 7<sup>th</sup> day and still present after 14 days
- Sustained levels of hFXN are found after 14 days in the cerebrospinal fluid of monkeys, suggesting CNS penetration



# Biodistribution in Healthy Cynomolgus Monkeys

Sustained levels of human FXN (hFXN) in peripheral tissues after 14 days of CTI-1601 dosing



- Treatment of monkeys with CTI-1601 results in sustained levels of hFXN in peripheral tissues that are accessible in the clinic
- FXN levels increase ~4X or more following CTI-1601 administration
  - For comparison, FA patients show FXN levels that range from ~20-40% of normal FXN levels depending on the tissue considered<sup>1</sup>
    - Heterozygous carriers show no phenotype and display levels of FXN representing ~2-3X higher than most FA patients<sup>1</sup>